Novel vaccine approaches to eradicate 

Malaria

 

News

January 2017

Successful

PH1 Clinical Trial

for GAP3KO Published

 

 

 

Why it matters

Every year, 300-500 million malaria infections cause more than  1 million deaths, of which more than 75 percent occur in Africa. Malaria causes 1 in 5 of all childhood deaths in Africa with 70% of the children killed by malaria under 5 years of age. It kills one child every thirty seconds - about 3000 children a day. Malaria devastates lives not only through death, but disability and loss of productivity, negatively impacting economies and compounding the effects of poverty. Economists estimate that the gross domestic product of African nations is reduced by $12 billion annually due to the debilitating effects of malaria.

Our Credo

To make a difference, malaria research must be transformed into treatments and prevention that includes vaccines.

• Vaccines and treatments must be safe, effective, affordable, and transportable to those who need them;

• Vaccines and treatments must not violate the trust of the people who receive them;

• Developing treatments and vaccines may require unconventional approaches to succeed and we must be willing to think creatively;

• This development effort will give all participants a chance to help alleviate the suffering of hundreds of millions of people worldwide;

• Much of the work has already been proven -

                                                                                                                       We are determined to succeed!

 

The Challenge

Despite over a century of work to control or eradicate this disease, malaria continues to take its devastating toll, largely in developing nations. 

According to the World Health Organization, there are currently no approved licensed malaria vaccines. Over 20 vaccine research projects are in clinical trials. Of these 20, the most advanced is in Phase 3 clinical trials, but is at best, 50% effective.  

A new approach to vaccine development is needed to finally eradicate this menacing disease.

 

  

We founded MalarVx to address the challenges of creating a safe, affordable, and highly effective malaria vaccine using innovative new technologies.